Amit Kumar Buys 21,000 Shares of Anixa Biosciences (NASDAQ:ANIX) Stock

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar purchased 21,000 shares of the business’s stock in a transaction on Friday, June 12th. The stock was acquired at an average price of $2.50 per share, for a total transaction of $52,500.00. Following the completion of the purchase, the chief executive officer owned 630,812 shares of the company’s stock, valued at $1,577,030. This represents a 3.44% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Anixa Biosciences Price Performance

Shares of NASDAQ ANIX opened at $2.48 on Tuesday. The business has a 50-day moving average of $2.78 and a two-hundred day moving average of $3.08. The company has a market capitalization of $84.37 million, a price-to-earnings ratio of -8.00 and a beta of 0.59. Anixa Biosciences Inc has a 1 year low of $2.32 and a 1 year high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings data on Wednesday, June 10th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. As a group, equities research analysts expect that Anixa Biosciences Inc will post -0.31 earnings per share for the current year.

Analysts Set New Price Targets

ANIX has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating on shares of Anixa Biosciences in a research note on Friday. Wall Street Zen downgraded shares of Anixa Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a research report on Wednesday, April 8th. Finally, Citigroup reiterated a “buy” rating on shares of Anixa Biosciences in a research note on Friday. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $8.50.

Institutional Trading of Anixa Biosciences

Large investors have recently made changes to their positions in the company. Bank of America Corp DE grew its stake in Anixa Biosciences by 1.7% during the 3rd quarter. Bank of America Corp DE now owns 213,955 shares of the company’s stock worth $706,000 after buying an additional 3,645 shares during the last quarter. GSA Capital Partners LLP lifted its stake in Anixa Biosciences by 4.9% in the third quarter. GSA Capital Partners LLP now owns 81,897 shares of the company’s stock valued at $270,000 after buying an additional 3,790 shares during the last quarter. Prosperity Wealth Management Inc. lifted its stake in Anixa Biosciences by 14.5% in the third quarter. Prosperity Wealth Management Inc. now owns 41,800 shares of the company’s stock valued at $138,000 after buying an additional 5,300 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Anixa Biosciences by 2.1% in the fourth quarter. Geode Capital Management LLC now owns 350,915 shares of the company’s stock valued at $1,095,000 after acquiring an additional 7,271 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in shares of Anixa Biosciences by 13.6% in the first quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock valued at $158,000 after acquiring an additional 7,300 shares during the period. 29.13% of the stock is owned by institutional investors and hedge funds.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.